Madhya Pradesh Online Journal

Angioimmunoblastic T-cell Lymphoma Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

 Breaking News
  • No posts were found

Angioimmunoblastic T-cell Lymphoma Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

May 11
19:15 2021
Angioimmunoblastic T-cell Lymphoma Market Analysis, Market Size, Epidemiology, Leading Companies And Competitive Analysis By Delveinsight

DelveInsight Business Research LLP
DelveInsight’s “Angioimmunoblastic T-Cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Angioimmunoblastic T-Cell Lymphoma, historical and forecasted epidemiology as well as the Angioimmunoblastic T-Cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Angioimmunoblastic T-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030

DelveInsight’s “Angioimmunoblastic T-cell Lymphoma – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the  Angioimmunoblastic T-cell Lymphoma, historical and forecasted epidemiology as well as the  Angioimmunoblastic T-cell Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Report:

  1. A study stated that AITL were reported to be more common in Europe (28.7%) compared to North America (16%) and Asia (17.9%). With respect to rarer extranodal forms (excluding primary cutaneous ALCL), most of the cases were diagnosed in Europe (2.8%) and only a few cases were reported in North America and Asia (1.6% and 1.5%, respectively). AITL is confirmed as a distinctive disorder in Europe, while in South America, NKCL and ALK-negative ALCL represent the most common subtypes.

  2. A study, which stated that AITL comprises 1-2% of non-Hodgkin lymphoma (NHL), 15-20% of peripheral T-cell lymphoma (PTCL). Geographically, more prevalent in Europe (28.7% of all PTCL) followed by Asia (17.9%) and North America (16.0%). As per the estimates, 0.05 new cases diagnosed per 100,000 patients in the United States per year.

Key benefits of the report:

1.  Angioimmunoblastic T-cell Lymphoma market report covers a descriptive overview and comprehensive insight of the  Angioimmunoblastic T-cell Lymphoma epidemiology and  Angioimmunoblastic T-cell Lymphoma market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2.  Angioimmunoblastic T-cell Lymphoma market report provides insights on the current and emerging therapies.

3.  Angioimmunoblastic T-cell Lymphoma market report provides a global historical and forecasted market covering drug outreach in 7 MM.

4. The  Angioimmunoblastic T-cell Lymphoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the  Angioimmunoblastic T-cell Lymphoma market.

Request for sample pages: https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

Angioimmunoblastic T-cell Lymphoma: Overview

Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). Lymphomas are cancer of white blood cells (lymphocytes) and can be divided depending on the type of cells, B-lymphocytes (B-cells) or T-lymphocytes (T-cells), AITL is a T-cell lymphoma.

The key player involved in the Angioimmunoblastic T-cell Lymphoma market:

  1.  Celgene, 

  2. Verastem, 

  3. Beigene, 

  4. Merck Sharp & Dohme Corp.

  5. Solasia Pharma, 

  6. Kura Oncology  

The launch of the emerging therapies is expected to significantly impact the  Angioimmunoblastic T-cell Lymphoma treatment scenario in the upcoming years:-

Drugs covered

  1. Azacitidine (CC-486)

  2. Copiktra (Duvelisib

  3. Tislelizumab (BGB-A317)

  4. Keytruda

  5. SP-02 (darinaparsin)

  6. Tipifarnib

Request a free sample report @https://www.delveinsight.com/sample-request/angioimmunoblastic-t-cell-lymphoma-atcl-market

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4.  Angioimmunoblastic T-cell Lymphoma Patient Share (%) Overview at a Glance

5.  Angioimmunoblastic T-cell Lymphoma Market Overview at a Glance

6.  Angioimmunoblastic T-cell Lymphoma Disease Background and Overview

7.  Angioimmunoblastic T-cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of  Angioimmunoblastic T-cell Lymphoma

9.  Angioimmunoblastic T-cell Lymphoma Current Treatment and Medical Practices

10. Unmet Needs

11.  Angioimmunoblastic T-cell Lymphoma Emerging Therapies

12.  Angioimmunoblastic T-cell Lymphoma Market Outlook

13. Country-Wise  Angioimmunoblastic T-cell Lymphoma Market Analysis (2017–2030)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18.  Angioimmunoblastic T-cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Angioimmunoblastic T-cell Lymphoma- Pipeline Insights, 2021

“Angioimmunoblastic T-cell Lymphoma Pipeline Insight, 2021” report by DelveInsight outlines comprehensive insights of present clinical development scenario and growth prospects across the  Angioimmunoblastic T-cell Lymphoma market. A detailed picture of the  Angioimmunoblastic T-cell Lymphoma pipeline landscape is provided, which includes the disease overview and  Angioimmunoblastic T-cell Lymphoma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/